Clinical Trials Logo

Recurrent Fallopian Tube Cancer clinical trials

View clinical trials related to Recurrent Fallopian Tube Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05335993 Active, not recruiting - Peritoneal Cancer Clinical Trials

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Start date: July 25, 2022
Phase: Phase 2
Study type: Interventional

Study to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.

NCT ID: NCT02785250 Active, not recruiting - Clinical trials for Recurrent Fallopian Tube Cancer

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Start date: April 2016
Phase: Phase 1/Phase 2
Study type: Interventional

T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating activity of the combination of these agents.